Q1 2019 EPS Estimates for NuVasive, Inc. Decreased by Svb Leerink (NUVA)

NuVasive, Inc. (NASDAQ:NUVA) – Equities research analysts at Svb Leerink reduced their Q1 2019 earnings per share (EPS) estimates for NuVasive in a report issued on Friday, April 12th. Svb Leerink analyst R. Newitter now forecasts that the medical device company will post earnings per share of $0.41 for the quarter, down from their previous forecast of $0.45. Svb Leerink also issued estimates for NuVasive’s Q2 2019 earnings at $0.57 EPS, FY2020 earnings at $2.54 EPS and FY2021 earnings at $2.83 EPS.

NuVasive (NASDAQ:NUVA) last released its quarterly earnings results on Wednesday, February 20th. The medical device company reported $0.69 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.63 by $0.06. NuVasive had a net margin of 1.13% and a return on equity of 14.60%. The firm had revenue of $288.30 million during the quarter, compared to analyst estimates of $290.85 million. During the same quarter last year, the business earned $0.56 EPS. The company’s revenue was up 6.1% compared to the same quarter last year.

Other research analysts have also issued research reports about the stock. BTIG Research lowered their price target on shares of NuVasive to $59.00 and set a “buy” rating for the company in a report on Thursday, January 17th. They noted that the move was a valuation call. Morgan Stanley lowered their price target on shares of NuVasive from $73.00 to $57.00 and set an “equal weight” rating for the company in a report on Wednesday, January 2nd. Zacks Investment Research upgraded shares of NuVasive from a “sell” rating to a “hold” rating in a report on Wednesday, January 2nd. BidaskClub lowered shares of NuVasive from a “buy” rating to a “hold” rating in a report on Tuesday, December 18th. Finally, Jefferies Financial Group lowered shares of NuVasive from a “buy” rating to a “hold” rating and set a $60.00 price target for the company. in a report on Tuesday, February 12th. Four analysts have rated the stock with a sell rating, seven have assigned a hold rating and seven have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $66.64.

NuVasive stock opened at $55.96 on Monday. The company has a debt-to-equity ratio of 0.72, a current ratio of 3.44 and a quick ratio of 1.92. NuVasive has a 52-week low of $43.51 and a 52-week high of $72.41. The company has a market cap of $2.90 billion, a price-to-earnings ratio of 25.09, a PEG ratio of 2.13 and a beta of 1.21.

Several large investors have recently added to or reduced their stakes in the company. Retirement Systems of Alabama increased its stake in shares of NuVasive by 0.8% in the 1st quarter. Retirement Systems of Alabama now owns 67,218 shares of the medical device company’s stock valued at $3,817,000 after acquiring an additional 546 shares in the last quarter. Louisiana State Employees Retirement System increased its stake in shares of NuVasive by 1.5% in the 1st quarter. Louisiana State Employees Retirement System now owns 13,800 shares of the medical device company’s stock valued at $784,000 after acquiring an additional 200 shares in the last quarter. Malaga Cove Capital LLC increased its stake in shares of NuVasive by 12.0% in the 1st quarter. Malaga Cove Capital LLC now owns 25,968 shares of the medical device company’s stock valued at $1,475,000 after acquiring an additional 2,790 shares in the last quarter. 6 Meridian increased its stake in shares of NuVasive by 32.2% in the 1st quarter. 6 Meridian now owns 10,200 shares of the medical device company’s stock valued at $579,000 after acquiring an additional 2,486 shares in the last quarter. Finally, American Century Companies Inc. bought a new stake in shares of NuVasive in the 4th quarter valued at $6,258,000.

NuVasive Company Profile

NuVasive, Inc, a medical device company, develops and markets minimally disruptive surgical products and procedurally integrated solutions for spine surgery. Its products focus on applications for spine fusion surgery, including ancillary products and services used to aid in the surgical procedure. The company's principal products include Maximum Access Surgery, a minimally disruptive surgical platform, which includes its software-driven nerve detection and avoidance systems, and intraoperative monitoring (IOM) services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics.

Featured Story: Is the Dow Jones Industrial Average (DJIA) still relevant?

Earnings History and Estimates for NuVasive (NASDAQ:NUVA)

Receive News & Ratings for NuVasive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit